Al18F-NOTA-octreotide

N/A

Report date: 2025/12/30 16:02:49

NME

Base Information

Drug NameAl18F-NOTA-octreotide

Drug Alias Name18F-AlF-NOTA-octreotideAl18F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotideAl18F-OCfluorine F 18-IMP-466fluorine F 18-NOTA octreotide +[9]

ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radionuclide Drug Conjugates +[5]

Mechanisms of ActionRadionuclide imaging enhancersSomatostatin receptor binders

TargetsSomatostatin receptor

Therapy Area/IndicationsAtherosclerosisStrokeCarotid Stenosis +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesUz Leuven

China Registration ClassN/A

Develop Information

Active CompaniesUniversitaire Ziekenhuizen Leuven

Inactive CompaniesN/A

Active IndicationsAtherosclerosisStrokeCarotid Stenosis +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A